 A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19Yogiraj Ray (),
Shekhar Ranjan Paul,
Purbita Bandopadhyay,
Ranit D’Rozario,
Jafar Sarif,
Deblina Raychaudhuri,
Debaleena Bhowmik,
Abhishake Lahiri,
Janani Srinivasa Vasudevan,
Ranjeet Maurya,
Akshay Kanakan,
Sachin Sharma,
Manish Kumar,
Praveen Singh,
Rammohan Roy,
Kausik Chaudhury,
Rajsekhar Maiti,
Saugata Bagchi,
Ayan Maiti,
Md. Masoom Perwez,
Abhinandan Mondal,
Avinash Tewari,
Samik Mandal,
Arpan Roy,
Moumita Saha,
Durba Biswas,
Chikam Maiti,
Ritwik Bhaduri,
Sayantan Chakraborty,
Biswanath Sharma Sarkar,
Anima Haldar,
Bibhuti Saha,
Shantanu Sengupta,
Rajesh Pandey,
Shilpak Chatterjee,
Prasun Bhattacharya,
Sandip Paul and
Dipyaman Ganguly ()
Nature Communications, 2022, vol. 13, issue 1, 1-9 Abstract: Abstract A single center open label phase 2 randomised control trial (Clinical Trial Registry of India No. CTRI/2020/05/025209) was done to assess clinical and immunological benefits of passive immunization using convalescent plasma therapy. At the Infectious Diseases and Beleghata General Hospital in Kolkata, India, 80 patients hospitalized with severe COVID-19 disease and fulfilling the inclusion criteria (aged more than 18 years, with either mild ARDS having PaO2/FiO2 200–300 or moderate ARDS having PaO2/FiO2 100–200, not on mechanical ventilation) were recruited and randomized into either standard of care (SOC) arm (N = 40) or the convalescent plasma therapy (CPT) arm (N = 40). Primary outcomes were all-cause mortality by day 30 of enrolment and immunological correlates of response to therapy if any, for which plasma abundance of a large panel of cytokines was quantitated before and after intervention to assess the effect of CPT on the systemic hyper-inflammation encountered in these patients. The secondary outcomes were recovery from ARDS and time taken to negative viral RNA PCR as well as to report any adverse reaction to plasma therapy. Transfused convalescent plasma was characterized in terms of its neutralizing antibody content as well as proteome. The trial was completed and it was found that primary outcome of all-cause mortality was not significantly different among severe COVID-19 patients with ARDS randomized to two treatment arms (Mantel-Haenszel Hazard Ratio 0.6731, 95% confidence interval 0.3010-1.505, with a P value of 0.3424 on Mantel-Cox Log-rank test). No adverse effect was reported with CPT. In severe COVID-19 patients with mild or moderate ARDS no significant clinical benefit was registered in this clinical trial with convalescent plasma therapy in terms of prespecified outcomes. Date: 2022 Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28064-7 Ordering information: This journal article can be ordered from DOI: 10.1038/s41467-022-28064-7 Access Statistics for this article Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie More articles in Nature Communications from Nature |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.